Baqsimi ® (glukagon näspulver)

För fullständig produktresumé för Baqsimi® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Kan Baqsimi® (Glucagon näspulver) användas hos patienter med insulinpumpar?

I de nasala glukagonstudierna använde vissa vuxna och pediatriska deltagare med typ 1 -diabetes mellitus insulinpumpar.

SE_cFAQ_NG034_INSULIN_PUMPS
SE_cFAQ_NG034_INSULIN_PUMPS
en-GB

Adult Pivotal Study 

A randomized, multicenter, open-label, crossover study compared nasal glucagon (NG) 3 mg with intramuscular (IM) glucagon as treatment for insulin-induced hypoglycemia in adults with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM).1

Fifty-seven participants with T1DM were using insulin pumps.1

Adult Real-World Use Study

A phase 3, open-label, multicenter, single-arm study evaluated the effectiveness and ease of use of NG 3 mg in the treatment of moderate or severe hypoglycemic events in adults with T1DM in a real-world setting.2

Seventy-two participants were using insulin pumps.3

Pediatric Pivotal Study

A randomized, multicenter, dose finding clinical study evaluated the ability of NG 2 mg and 3 mg doses compared with glucagon IM to increase the blood glucose (BG) after insulin-induced reduction in BG in children and adolescents (aged 4 to <17 years) with T1DM.4

  • 10 participants aged 4 to <8 years
  • 16 participants aged 8 to <12 years, and
  • 9 participants aged 12 to <17 years

were using insulin pumps.4

References

1Rickels MR, Ruedy KJ, Foster NC, et al; T1D Exchange Intranasal Glucagon Investigators. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264-270. https://doi.org/10.2337/dc15-1498

2Seaquist ER, Dulude H, Zhang XM, et al. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab. 2018;20(5):1316-1320. https://doi.org/10.1111/dom.13278

3Seaquist ER, Dulude H, Zhang MX et al. Nasal glucagon for the treatment of moderate-to-severe hypoglycaemic episodes in real-world settings in adults with type 1 diabetes. Poster presented at: 53rd European Association for the Study of Diabetes (EASD): September 11-15, 2017; Lisbon, Portugal.

4Sherr JL, Ruedy KJ, Foster NC, et al; T1D Exchange Intranasal Glucagon Investigators. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555-562. https://doi.org/10.2337/dc15-1606

Datum fӧr senaste ӧversyn 2019 M07 24


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss